EverSource Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

EverSource Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3K	Buy	39 +6	+18%	+$1.41K	﹤0.01%	2779
2026 Q1	$6.59K	Sell	33 -6	-15%	-$1.19K	﹤0.01%	3130
2025 Q4	$7.37K	Sell	39 -35	-47%	-$6.72K	﹤0.01%	2943
2025 Q3	$13.1K	Sell	74 -2	-3%	-$297	﹤0.01%	2664
2025 Q2	$8.64K	Buy	76 +32	+73%	+$3.42K	﹤0.01%	2893
2025 Q1	$4.63K	Buy	44 +12	+38%	+$1.36K	﹤0.01%	2534
2024 Q4	$3.43K	Hold	32	–	–	﹤0.01%	2507
2024 Q3	$3.2K	Hold	32	–	–	﹤0.01%	2396
2024 Q2	$3.49K	Buy	32 +2	+7%	+$159	﹤0.01%	2346
2024 Q1	$2.1K	Buy	30 +21	+233%	+$1.55K	﹤0.01%	2370
2023 Q4	$643	Buy	+9	New	+$531	﹤0.01%	2478
2022 Q1	–	Sell	-99	Closed	-$10K	–	1787
2021 Q4	$10K	Buy	+99	New	+$9.15K	﹤0.01%	964

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's LGND Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Ligand Pharmaceuticals (LGND) stake by 18% in Q2 2026, buying an estimated $1.41K and bringing the position to 39 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2779.

EverSource Wealth Advisors first reported a position in LGND in Q4 2021 and has held it in 12 quarters since. The position peaked at $13.1K in Q3 2025. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

EverSource Wealth Advisors held 39 shares of Ligand Pharmaceuticals worth $12.3K as of Q2 2026.
EverSource Wealth Advisors bought 6 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.41K.
Ligand Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2779 holding.
EverSource Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
EverSource Wealth Advisors's Ligand Pharmaceuticals position peaked at $13.1K in Q3 2025.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.